NCT06693791View on ClinicalTrials.gov

Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

December 1, 2026

Conditions
Platelet Recovery After Umbilical Cord Blood Transplantation
Interventions
DRUG

Romiplostim N01

Romiplostim N01 was administered subcutaneously once weekly from +1 day to +28 days after UCBT at a recommended starting dose of 5µg/Kg (maximum single dose not to exceed 250µg) for a total of 4 administrations, with the option of continuation of dosing/switching/discontinuing after +28 days, depending on the patient's platelet profile.

Trial Locations (1)

230036

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV

NCT06693791 - Romiplostim N01 for Platelet Recovery in Adult Hematologic Malignancies Patients Undergoing UCBT | Biotech Hunter | Biotech Hunter